Compare JetBlue Airways Corporation (JBLU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Recursion Pharmaceuticals Inc — how do they compare? JetBlue Airways Corporation trades at $3.87 (market cap $1.48B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| JBLU | RXRX | |
|---|---|---|
Market Cap | $1.48B | $2.14B |
Volume | 30,275,693 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $6.46 | $6.79 |
52-Week Low | $3.92 | $2.84 |
Typical Hold Time | 44 Days | 22 Days |
Enterprise Value | $8.84B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.97, down 1.49% today, with a bearish technical outlook despite oversold RSI levels. The airline faces fundamental challenges with consecutive quarterly losses, negative profit margins (-9.32%), and elevated debt levels (debt-to-asset ratio of 51.28% in 2025). Recent developments include route expansion to Colombia and the launch of premium BlueFirst seating, but operational cash flow remains negative (-$94M in 2025).
The investment outlook is cautious given persistent losses and high leverage, though the current valuation (P/S 0.15, P/B 0.93) appears discounted. Analyst consensus is mixed with a $5.89 price target (48% upside) but predominantly Hold ratings (62%). Key risks include fuel cost volatility, competitive pressure, and macroeconomic sensitivity to travel demand.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
